{
    "paper_id": "f7d49461db82053b2258177ac000d595bf0ac808",
    "metadata": {
        "title": "Title: COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking",
        "authors": [
            {
                "first": "Giuseppe",
                "middle": [],
                "last": "Magro",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University \"Magna Graecia\" of Catanzaro",
                    "location": {
                        "country": "Italy"
                    }
                },
                "email": "g1us3pp3m4gr0@gmail.com"
            }
        ]
    },
    "abstract": [
        {
            "text": "SARS-CoV-2 is the agent responsible for COVID-19. The infection can be dived into three phases: mild infection, the pulmonary phase and the inflammatory phase. Treatment options for the pulmonary phase include: Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir. The inflammatory phase includes therapeutic options like Tocilizumab, Anakinra, Baricitinib, Eculizumab, Emapalumab and Heparin. Human clinical trials are starting to show some results, in some cases like that of Remdesivir these are controversial. Coagulopathy is a common complication in severe cases, inflammation and coagulation are intertwined and cross-talking between these two responses is known to happen. A possible amplification of J o u r n a l P r e -p r o o f 2 this cross-talking is suggested to be implicated in the severe cases that show both a cytokine storm and coagulopathy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Coronaviruses are enveloped, positive-sense, single stranded RNA viruses that are distributed broadly among humans which cause respiratory, enteric, hepatic, and neurologic diseases 1 . SARS-CoV-2 is the seventh member of the family of corona viruses that infects humans, after MERS-CoV and SARS-CoV-1, it is a beta coronavirus of group 2B with over 70% similarity in genetic sequence to SARS-CoV-1 2 . Some studies show that angiotensin-convertin enzyme 2 (ACE2) is the receptor for SARS-CoV-2 3, 4 . Structural analysis of the spike (S) protein of this new virus showed that its S protein is the one binding to the angiotensinconverting enzyme 2 (ACE2) receptor on human cells 5 . The incubation period is generally 3-7 days (within 14 days) 6 , mean incubation period is 5.2 days and 97,5% of patients who develop symptoms do so in the first 11,5 days 7, 8 . Symptoms of SARS-CoV-2 infection are nonspecific. The most common ones are onset on fever, weakness and dry cough. Less common symptoms are headache, myalgia, fatigue, oppression in the chest, dyspnea, sputum production, diarrhea 9 , confusion, sore throat, rhinorrhea, chest pain, nausea and vomiting 10 . Up to 50% of patients develop shortness of breath. Acute respiratory distress syndrome (ARDS)",
            "cite_spans": [
                {
                    "start": 495,
                    "end": 497,
                    "text": "3,",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 498,
                    "end": 499,
                    "text": "4",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 679,
                    "end": 680,
                    "text": "5",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 744,
                    "end": 745,
                    "text": "6",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 855,
                    "end": 857,
                    "text": "7,",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 858,
                    "end": 859,
                    "text": "8",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 1092,
                    "end": 1093,
                    "text": "9",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 1164,
                    "end": 1166,
                    "text": "10",
                    "ref_id": "BIBREF10"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "is not an uncommon complication when disease can't be controlled 6 . The percentage of patients requiring ARDS treatment is about 10% for those who are hospitalized and symptomatic. Some patients are known to be asymptomatic carriers of the infection showing no clinical signs 6 . Usually severe patients are older and have chronic diseases, among those the most common associated diseases in severe cases are hypertension and cardiovascular diseases 11 . Total white blood count, lymphocytes, and platelets are lower than the average with extended activated thromboplastin time, increase C-reactive protein and muscle J o u r n a l P r e -p r o o f enzyme level. Lymphocytes decrease with diseases progression. Secretion of cytokine, such as IL1B, IL1RA, IL6, IL7, IL8, IL-2R, TNF-alfa, known as cytokine storm, is associated with disease severity 6, 11, 12 .",
            "cite_spans": [
                {
                    "start": 65,
                    "end": 66,
                    "text": "6",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 277,
                    "end": 278,
                    "text": "6",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 451,
                    "end": 453,
                    "text": "11",
                    "ref_id": "BIBREF11"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Here we present the drugs used in each phase. Another possible approach is to discuss every drug related to every phase of viral infection (Adhesion, Entry, Endocytosis, Replication, Protein cleavage, Cytokine Storm, Free circulation) as done in a previous study by the author 13 .",
            "cite_spans": [
                {
                    "start": 277,
                    "end": 279,
                    "text": "13",
                    "ref_id": "BIBREF13"
                }
            ],
            "ref_spans": [],
            "section": "Treatment: the pulmonary phase"
        },
        {
            "text": "We basically have three phases of infection, the first one is the mild infection phase which only requires symptomatic treatment. Patient shows fever, with or without respiratory symptoms, no hypoxemia and negative imaging. This patient needs testing only if there is a high risk of contagion. It is important to perform a 6-minutes walking test before patient discharge to attest there is no exertional hypoxemia.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment: the pulmonary phase"
        },
        {
            "text": "Pulmonary phase is the second phase which requires mostly antiviral treatment. Patient shows fever, bilateral pulmonary consolidations or hypoxemia. This patient needs to be hospitalized. The currently available options include: Hydroxychloroquine/Azithromycin, Remdesivir, Lopinavir/Ritonavir.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment: the pulmonary phase"
        },
        {
            "text": "Hydroxychloroquine alters the process of endocytosis. Hydroxychloroquine is a derivate of chloroquine which alters pH (by increasing it) of endosome and lysosome essential for membrane fusion between host cell and the virus. Due to their basic properties and consequent disruption of cellular vesicle compartments, chloroquine and hydroxychloroquine may also inhibit virion budding and forming of mature virions 14 . An in vitro experiment showed that in chloroquine treated cells endosomes vesicles were abnormally enlarged 15 .",
            "cite_spans": [
                {
                    "start": 412,
                    "end": 414,
                    "text": "14",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 525,
                    "end": 527,
                    "text": "15",
                    "ref_id": "BIBREF15"
                }
            ],
            "ref_spans": [],
            "section": "Hydroxychloroquine"
        },
        {
            "text": "This indicates an altered maturation process of endosomes, blocking endocytosis, resulting in failure of further transport of virions to the replication site 15 . Hydroxychloroquine is being tested with azithromycin, and the association has shown some result in viral load reduction, but concern about prolonged QT interval arise with the association 16 . Chloroquine and hydroxychloroquine appear to block viral entry into cells not only by inhibition of endosomal acidification, but also by inhibition of glycosylation of host receptors and proteolytic processing, a critical passage of virus-cell ligand recognition. They may also impair the correct J o u r n a l P r e -p r o o f maturation and recognition of viral antigens by antigen-presenting cells (APCs) that require endosomal acidification for antigen processing 14 . This could be the explanation as to why they also have immunomodulatory effect through attenuation of cytokine production and inhibition of autophagy and lysosomal activity in host cells 17, 18 . Hydroxychloroquine inhibits IL-6, IL1-beta and TNF-alfa release 14 , and it showed also anti-thrombotic properties interfering with platelet aggregation and blood clotting proteins 14 .",
            "cite_spans": [
                {
                    "start": 158,
                    "end": 160,
                    "text": "15",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 351,
                    "end": 353,
                    "text": "16",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 824,
                    "end": 826,
                    "text": "14",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 1016,
                    "end": 1019,
                    "text": "17,",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 1020,
                    "end": 1022,
                    "text": "18",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 1089,
                    "end": 1091,
                    "text": "14",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 1206,
                    "end": 1208,
                    "text": "14",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "Hydroxychloroquine"
        },
        {
            "text": "An open-label nonrandomized study of 36 patients reported improved virologic clearance with hydroxychloroquine. They also reported that the addition of azithromycin to hydroxychloroquine resulted in superior viral clearance in some patients 16, 19 . Azithromycin has been shown to be active in vitro against Zika and Ebola viruses 16, 20, 21 , and to prevent severe respiratory tract infections when administrated to patients suffering viral infections 22 . Another prospective randomized study of 30 patients showed no benefit and no difference in virologic outcomes between the treated patients vs non treated 23 . Given the role of iron in several human viral infections, a potential involvement of Hydroxychloroquine in iron homeostasis in SARS-CoV-2 infection has been suggested 14 . Chloroquine and hydroxychloroquine are given orally and are generally well tolerated, however they can cause rare and serious effects such as QTc prolongation, hypoglycemia, neuropsychiatric effects and retinopathy. Known major drug-drug interactions happen with drugs who are also substrates of CYP2D6 and CYP3A4 24 . A randomized clinical trial of 62 patients from China suffering from COVID-19 showed how hydroxychloroquine shortens time to clinical recovery and absorption of pneumonia (ChiCTR2000029559) 25 . One study (NCT04261517, Phase 3) 26 showed positive preliminary outcomes, even though the sample was small.",
            "cite_spans": [
                {
                    "start": 241,
                    "end": 244,
                    "text": "16,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 245,
                    "end": 247,
                    "text": "19",
                    "ref_id": null
                },
                {
                    "start": 331,
                    "end": 334,
                    "text": "16,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 335,
                    "end": 338,
                    "text": "20,",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 339,
                    "end": 341,
                    "text": "21",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 453,
                    "end": 455,
                    "text": "22",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 612,
                    "end": 614,
                    "text": "23",
                    "ref_id": null
                },
                {
                    "start": 784,
                    "end": 786,
                    "text": "14",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 1103,
                    "end": 1105,
                    "text": "24",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 1298,
                    "end": 1300,
                    "text": "25",
                    "ref_id": "BIBREF26"
                }
            ],
            "ref_spans": [],
            "section": "Hydroxychloroquine"
        },
        {
            "text": "Targeting the RNA-dependent RNA polymerase (RdRp) showed low specificity and low potency, nevertheless the most promising drug belonging to this class is Remdesivir 27, 28 . Remdesivir is one of the most promising antiviral in fighting SARS-CoV-2. It is an adenosine nucleotide analogue prodrug with broadspectrum activity against pneumoviruses, filoviruses, paramyxoviruses and coronaviruses 29 . It can inhibit J o u r n a l P r e -p r o o f the replication of multiple coronaviruses in respiratory epithelial cells. A recent study showed Remdesivir can compete with natural counterpart ATP. Once it is added to the growing chain, it does not cause an immediate stop but it stops the strand after 3 more nucleotides are added 28 . Remdesivir is currently being tested for antiviral activity against Ebola virus 30 ",
            "cite_spans": [
                {
                    "start": 165,
                    "end": 168,
                    "text": "27,",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 169,
                    "end": 171,
                    "text": "28",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 393,
                    "end": 395,
                    "text": "29",
                    "ref_id": "BIBREF29"
                },
                {
                    "start": 728,
                    "end": 730,
                    "text": "28",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 813,
                    "end": 815,
                    "text": "30",
                    "ref_id": "BIBREF30"
                }
            ],
            "ref_spans": [],
            "section": "Remdesivir"
        },
        {
            "text": "The Main protease is another suitable drug target, one example in doing so is the combination of Lopinavir/Ritonavir 27 . Lopinavir/ritonavir is a medication for the human immunodeficiency virus (HIV) used in combination with other medications to treat adults and children who are infected with HIV-1. Lopinavir in particular is an HIV-1 protease inhibitor, its combination with ritonavir has shown to be effective against SARS-CoV-1 in patients and in tissue culture, via inhibition of 3-chymotripsin-like protease (3CLpro), the main protease 35, 36 . The combination of the two also reduced clinical scores and disease progression in animals infected with MERS-CoV 37 . Previous studies showed the combination of lopinavir and ritonavir to be of some use for SARS-CoV-1 and MERS-CoV infected patients 38 . Clinical studies in SARS-CoV-1 were associated with reduced mortality and intubation rates 38, 39 . Both anti-HIV drugs interacted well with the residues at the active site of SARS-CoV-2 3CLpro. Ritonavir showed a somewhat higher number atomic contacts, a somewhat higher binding efficiency, and higher number of key binding residues compared to lopinavir, which correspond with the slightly lower water accessibility at the 3CLpro active site 40 ",
            "cite_spans": [
                {
                    "start": 544,
                    "end": 547,
                    "text": "35,",
                    "ref_id": "BIBREF35"
                },
                {
                    "start": 548,
                    "end": 550,
                    "text": "36",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 667,
                    "end": 669,
                    "text": "37",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 803,
                    "end": 805,
                    "text": "38",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 899,
                    "end": 902,
                    "text": "38,",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 903,
                    "end": 905,
                    "text": "39",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 1252,
                    "end": 1254,
                    "text": "40",
                    "ref_id": "BIBREF40"
                }
            ],
            "ref_spans": [],
            "section": "Lopinavir/Ritonavir"
        },
        {
            "text": "The inflammatory phase is the third phase, which leads to the most common complication of COVID-19",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment: the inflammatory phase"
        },
        {
            "text": "which is ARDS. Patient shows fever, severe hypoxemia with partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio <300 and multiple pulmonary consolidations. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Treatment: the inflammatory phase"
        },
        {
            "text": "High levels of interleukin 6 (IL-6) and Interleukin 8 (IL-8) were found in the acute stage associated with lung lesions in SARS-CoV-1 patients. Especially IL-6 can induce the hyper-inflammatory response due to the SARS-CoV-1 invasion of the respiratory tract 47 . Interestingly, in human epithelial cells, SARS-CoV-1 was able to induce greater IL-6 when compared to influenza A virus 48 . Although in some murine viral infections IL-6 plays a protective and essential role in the resolution process, in others like in SARS-CoV-1 high levels of IL-6",
            "cite_spans": [
                {
                    "start": 259,
                    "end": 261,
                    "text": "47",
                    "ref_id": "BIBREF47"
                },
                {
                    "start": 384,
                    "end": 386,
                    "text": "48",
                    "ref_id": "BIBREF48"
                }
            ],
            "ref_spans": [],
            "section": "Tocilizumab and other IL-6 Receptor inhibitors"
        },
        {
            "text": "were associated with severe inflammation and correlated with mortality in the mice 49, 50 . This happens also with SARS-CoV-2 in COVID-19 patients: some retrospective and meta-analysis studies show how elevated J o u r n a l P r e -p r o o f IL-6 and C-reactive protein (CRP) correlate with mortality and severe disease in comparison to moderate disease [51] [52] [53] [54] . More evidence suggests that critically ill patients with severe respiratory failure and SARS-CoV-2 have either immune dysregulation or macrophage-activation syndrome, both of which are characterized by pro-inflammatory cytokines. The immune dysregulation, in particular, is driven by the Interleukin-6 (IL- 6) and not by Interleukin-1beta (IL-1beta) 54 . Interestingly, among all SARS-CoV-1 structural proteins (N, S, E and M), the nucleocapsid protein (N) significantly induced the activation of IL-6 promotor in human airway epithelial cell cultures 55 . IL-6 gene expression is activated by the N protein which binds to the NF-kB regulatory element on IL-6 promoter and facilitates its translocation from cytosol to nucleus. The N protein is essential for IL-6 secretion to happen, since deletion of the C-terminus of the N protein resulted in the loss of function in the activation of IL-6 55 . This again points towards excessive activation of the innate immune response. Another proof of that is the damage shown to the pulmonary interstitial arteriolar walls that is more associated with the inflammatory response rather than the pathogenic effect of CoVs 56 Major effects include hematologic effects, infections, gastrointestinal perforations and hypersensitivity reactions. Interactions with several CYP450 isoenzymes are described 24 . Interestingly, Tocilizumab targets both IL-6 receptor (IL-6R) forms: the soluble one (sIL-6R) and the membrane bound one (mIL-6R). Those two forms seem to work in very divergent ways, since the soluble one is believed to be pro-inflammatory, and the membrane bound IL-6 Receptor is believed to act in an anti-inflammatory way 58 , inhibiting only the pro-inflammatory one could then be a better option then targeting them both 59 . Sarilumab, another antibody against IL-6 receptor used in rheumatoid arthritis 60 , is being tested in a multicenter, double-blind, J o u r n a l P r e -p r o o f clinical phase 2/3 in patients with severe COVID-19 (NCT04315298) 24 . Other drugs that showed potential inhibition of IL-6 related JAK/STAT pathway are: Fingolimod which showed to inhibit proliferation and epithelial-mesenchymal transition in sacral chordoma by inactivating IL-6/STAT3 signaling 61 , a clinical trial in COVID-19 patients is ongoing (NCT04280588, Phase2) 26 ; glatiramer acetate showed potential to downregulate both IL-17 and IL-6 in the central nervous system in an autoimmune encephalitis model 62 .",
            "cite_spans": [
                {
                    "start": 83,
                    "end": 86,
                    "text": "49,",
                    "ref_id": "BIBREF49"
                },
                {
                    "start": 87,
                    "end": 89,
                    "text": "50",
                    "ref_id": "BIBREF50"
                },
                {
                    "start": 354,
                    "end": 358,
                    "text": "[51]",
                    "ref_id": "BIBREF51"
                },
                {
                    "start": 359,
                    "end": 363,
                    "text": "[52]",
                    "ref_id": "BIBREF52"
                },
                {
                    "start": 364,
                    "end": 368,
                    "text": "[53]",
                    "ref_id": null
                },
                {
                    "start": 369,
                    "end": 373,
                    "text": "[54]",
                    "ref_id": "BIBREF53"
                },
                {
                    "start": 683,
                    "end": 685,
                    "text": "6)",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 726,
                    "end": 728,
                    "text": "54",
                    "ref_id": "BIBREF53"
                },
                {
                    "start": 928,
                    "end": 930,
                    "text": "55",
                    "ref_id": "BIBREF54"
                },
                {
                    "start": 1270,
                    "end": 1272,
                    "text": "55",
                    "ref_id": "BIBREF54"
                },
                {
                    "start": 1539,
                    "end": 1541,
                    "text": "56",
                    "ref_id": "BIBREF55"
                },
                {
                    "start": 1717,
                    "end": 1719,
                    "text": "24",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 2048,
                    "end": 2050,
                    "text": "58",
                    "ref_id": "BIBREF57"
                },
                {
                    "start": 2149,
                    "end": 2151,
                    "text": "59",
                    "ref_id": "BIBREF58"
                },
                {
                    "start": 2233,
                    "end": 2235,
                    "text": "60",
                    "ref_id": "BIBREF59"
                },
                {
                    "start": 2383,
                    "end": 2385,
                    "text": "24",
                    "ref_id": "BIBREF25"
                }
            ],
            "ref_spans": [],
            "section": "Tocilizumab and other IL-6 Receptor inhibitors"
        },
        {
            "text": "Another option in fighting the cytokine storm is targeting IL-1 with Canakinumab, a monoclonal antibody against IL-1-beta, which is being approved by the Italian drug agency (AIFA) in COVID-19 pneumonia. It is used for the treatment of familial Mediterranean fever and it has been shown to be of use in atherosclerotic diseases for its anti-inflammatory properties 63, 64 . A clinical phase 2 trial is ongoing in patients with COVID-19 pneumonia with Canakinumab (NCT04362813) 26 .",
            "cite_spans": [
                {
                    "start": 365,
                    "end": 368,
                    "text": "63,",
                    "ref_id": "BIBREF61"
                },
                {
                    "start": 369,
                    "end": 371,
                    "text": "64",
                    "ref_id": "BIBREF62"
                }
            ],
            "ref_spans": [],
            "section": "Canakinumab, Anakinra and Emapalumab"
        },
        {
            "text": "Anakinra is also another option in targeting IL-1 Receptor, which is used for rheumatoid arthritis 65 . Anakinra is being tested with Tocilizumab in a phase 2 clinical trial (NCT04339712) 26 . It is also being tested in COVID-19 patients combined with Emapalumab (NCT04324021, Phase2/3 multicenter randomized clinical trial) 26 .",
            "cite_spans": [
                {
                    "start": 99,
                    "end": 101,
                    "text": "65",
                    "ref_id": "BIBREF63"
                },
                {
                    "start": 188,
                    "end": 190,
                    "text": "26",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Canakinumab, Anakinra and Emapalumab"
        },
        {
            "text": "Emapalumab is a human monoclonal antibody against interferon gamma which acts to block its binding to cell surface receptors and activation of inflammatory signals, it is used to treat the severe inflammatory condition of hemophagocytic lymphohistiocytosis (HLH) 66 .",
            "cite_spans": [
                {
                    "start": 263,
                    "end": 265,
                    "text": "66",
                    "ref_id": "BIBREF64"
                }
            ],
            "ref_spans": [],
            "section": "Canakinumab, Anakinra and Emapalumab"
        },
        {
            "text": "After the SARS-CoV-2 infection, CD4+T lymphocytes are rapidly activated to become pathogenic T helper PT and APTT compared to survivors on admission; more than 70% of non survivors met the criteria of disseminated intravascular coagulation (DIC) during hospitalization 71 . It has also become clear that COVID-19-related DIC is not a bleeding diathesis but rather a predominantly prothrombotic DIC with high venous thromboembolism rates, elevated D-dimer and fibrinogen levels, low anti-thrombin levels. The use of anticoagulant therapy with heparin was shown to decrease mortality 72 . This was especially so in patients who meet the sepsis induced coagulopathy (SIC) criteria (a score >= 4 is required) and in patients with markedly elevated D-dimer 72 . This suggest that Low molecular weight heparin (LMWH) at prophylactic dose should be considered in patients meeting SIC criteria and elevated D-dimer. Heparin showed, besides its primary known use, to have also anti-inflammatory properties [73] [74] [75] , that could be of therapeutic value in those patients with severe lung inflammation and impaired pulmonary exchange. ARDS is a common complication of COVID-19. Activation of coagulation system has been linked to ARDS onset. It has been shown that the median plasma concentrations of tissue factor and plasminogen activator inhibitor-1 were J o u r n a l P r e -p r o o f significantly higher at day seven in patients with ARDS, as compared to non-ARDS 76 . Coagulopathy arises from thrombin generation mediated by localized tissue factor, and depression of fibrinolysis mediated by plasminogen activator in the lungs, in accordance with an increase in plasminogen activator inhibitor-1 (PAI-1) 76, 77 . This again points towards how heparin might be helpful in fighting this coagulopathy. Another interesting therapeutic property of heparin is its supposed antiviral role 78 . Heparin showed to inhibit infection in experimental vero cells injected with sputum from a patient with SARS-CoV-1 pneumonia 79 .",
            "cite_spans": [
                {
                    "start": 269,
                    "end": 271,
                    "text": "71",
                    "ref_id": "BIBREF69"
                },
                {
                    "start": 582,
                    "end": 584,
                    "text": "72",
                    "ref_id": "BIBREF70"
                },
                {
                    "start": 752,
                    "end": 754,
                    "text": "72",
                    "ref_id": "BIBREF70"
                },
                {
                    "start": 997,
                    "end": 1001,
                    "text": "[73]",
                    "ref_id": "BIBREF71"
                },
                {
                    "start": 1002,
                    "end": 1006,
                    "text": "[74]",
                    "ref_id": "BIBREF72"
                },
                {
                    "start": 1007,
                    "end": 1011,
                    "text": "[75]",
                    "ref_id": "BIBREF73"
                },
                {
                    "start": 1465,
                    "end": 1467,
                    "text": "76",
                    "ref_id": "BIBREF74"
                },
                {
                    "start": 1707,
                    "end": 1710,
                    "text": "76,",
                    "ref_id": "BIBREF74"
                },
                {
                    "start": 1711,
                    "end": 1713,
                    "text": "77",
                    "ref_id": "BIBREF75"
                },
                {
                    "start": 1885,
                    "end": 1887,
                    "text": "78",
                    "ref_id": "BIBREF76"
                }
            ],
            "ref_spans": [],
            "section": "Gimsilumab"
        },
        {
            "text": "Recently, Cui and colleagues, reported the prevalence of venous thromboembolism (VTE) in 81 severe COVID-19 patients with pneumonia admitted in the intensive care unit. The incidence in these patients of VTE (not under thromboprophylaxis) was 25% and eventually 40% of them died 80 . Increased levels of D-Dimer predicted VTE with a sensitivity of 85%, specificity of 88.5% and negative predictive value of 94% 80 .",
            "cite_spans": [
                {
                    "start": 279,
                    "end": 281,
                    "text": "80",
                    "ref_id": "BIBREF78"
                },
                {
                    "start": 411,
                    "end": 413,
                    "text": "80",
                    "ref_id": "BIBREF78"
                }
            ],
            "ref_spans": [],
            "section": "Gimsilumab"
        },
        {
            "text": "The prevalence of VTE in ICU patients with COVID-19 pneumonia reported by Cui is higher than the prevalence of VTE associated with other diseases: in a meta-analysis of seven studies including 1783 ICU patients, the mean rate of VTE diagnosis was 12.7, thus suggesting a direct role of COVID-19 in VTE pathogenesis 81 . Moreover, coagulopathy is known to happen in the majority of patients who die of COVID-19 71 . This suggests that severe COVID-19 patients are at high VTE risk and mortality risk and anticoagulant therapy might improve their prognosis 82 ",
            "cite_spans": [
                {
                    "start": 315,
                    "end": 317,
                    "text": "81",
                    "ref_id": "BIBREF79"
                },
                {
                    "start": 410,
                    "end": 412,
                    "text": "71",
                    "ref_id": "BIBREF69"
                },
                {
                    "start": 555,
                    "end": 557,
                    "text": "82",
                    "ref_id": "BIBREF80"
                }
            ],
            "ref_spans": [],
            "section": "Gimsilumab"
        },
        {
            "text": "The activation of both the immune system and the coagulation system are not simply associated in time, but there is extensive crosstalk between the two systems 87 . Upon injury by a micro-organism, immune cells are recruited and many pro-inflammatory cytokines are secreted, and these cytokines are key mediators of activation of coagulation 88 . Moreover, inflammation not only leads to activation of coagulation, but coagulation also affects inflammatory activity 87 . Acute infections can alter hemodynamics, clotting and fibrinolytic systems leading to ischemic events 89 . This is what might happen with SARS-CoV-2 infection too.",
            "cite_spans": [
                {
                    "start": 342,
                    "end": 344,
                    "text": "88",
                    "ref_id": "BIBREF85"
                },
                {
                    "start": 466,
                    "end": 468,
                    "text": "87",
                    "ref_id": "BIBREF84"
                },
                {
                    "start": 573,
                    "end": 575,
                    "text": "89",
                    "ref_id": "BIBREF86"
                }
            ],
            "ref_spans": [],
            "section": "Coagulation system and cytokine storm: cross-talking"
        },
        {
            "text": "High levels of IL-6 and IL-8 have been associated to SARS-CoV-1 and SARS-CoV-2 as already mentioned above, and high levels of these cytokines also correlate with mortality. There is also a clear connection that has been proven between inflammatory events and the development of thrombovascular disease in many clinical scenarios 90 . Complications like venous thromboembolism (VTE) has been connected to inflammation and some results showed that patients with VTE have higher plasma levels of interleukin-8 (IL-8) then those without VTE 90, 91 . Both IL-6 and IL-8 have a role in activation of coagulation, and higher levels of these cytokines may correlate with higher rate of VTE events 90, 91 , this also might happen in the lungs in patients with severe COVID-19 pneumonia. It has been reported how IL-8 production directly correlates with thrombin-antithrombin (TAT) complex 92 . Abnormal clot lysis was observed in the presence of IL-1 beta, IL-6 and IL-8, using thromboelastography. Interestingly, IL-8 shows the most significant results in thromboelastography (TEG) analysis making the clot form faster (hypercoagulation), with an increase in cross-linking fibrin fibers. IL-8 showed also to be able to alter erythrocyte structure and its addition produced a clot with an increased time to clot formation that is less stable and more prone to early lysis 88 .",
            "cite_spans": [
                {
                    "start": 329,
                    "end": 331,
                    "text": "90",
                    "ref_id": "BIBREF87"
                },
                {
                    "start": 537,
                    "end": 540,
                    "text": "90,",
                    "ref_id": "BIBREF87"
                },
                {
                    "start": 541,
                    "end": 543,
                    "text": "91",
                    "ref_id": "BIBREF88"
                },
                {
                    "start": 689,
                    "end": 692,
                    "text": "90,",
                    "ref_id": "BIBREF87"
                },
                {
                    "start": 693,
                    "end": 695,
                    "text": "91",
                    "ref_id": "BIBREF88"
                },
                {
                    "start": 880,
                    "end": 882,
                    "text": "92",
                    "ref_id": "BIBREF89"
                }
            ],
            "ref_spans": [],
            "section": "Coagulation system and cytokine storm: cross-talking"
        },
        {
            "text": "Thus, the clotting risk with increased levels of IL-8 might result in the presence of small thrombi, with an increased risk for vessels occlusion as observed in some COVID-19 patients autopsies 93 . Inflammation stimulates coagulation by leading to intravascular tissue factor expression and down regulation of the fibrinolytic pathway 94 . Interestingly, IL-6 is responsible for one of the main mechanism whereby inflammation activates coagulation by inducing tissue factor (TF) expression 87, 95, 96 . Moreover IL-6 can increase the expression of fibrinogen, factor VIII and VWF, activation of endothelial cells and increase platelets production and reduce the levels of inhibitors of haemostasis such as antithrombin and protein S 97 . It has been reported how IL-6 can also elicits a dose-dependent acceleration of thrombus development in arterioles of a WT mice 98 . IL-6 can also cause the clot to form faster and in a less stable form, and causes a more hypercoagulable clot then IL-1 beta; but IL-8 is still the most potent procoagulant cytokine between those three: causing the most significant changes at all levels of coagulation, including fibrin, thrombin and cellular interactions 99 . IL-8 promotes procoagulant activity, by triggering also platelet activation 100 . This is evidence of how cytokines and inflammation activate coagulation.",
            "cite_spans": [
                {
                    "start": 194,
                    "end": 196,
                    "text": "93",
                    "ref_id": "BIBREF90"
                },
                {
                    "start": 336,
                    "end": 338,
                    "text": "94",
                    "ref_id": "BIBREF91"
                },
                {
                    "start": 491,
                    "end": 494,
                    "text": "87,",
                    "ref_id": "BIBREF84"
                },
                {
                    "start": 495,
                    "end": 498,
                    "text": "95,",
                    "ref_id": "BIBREF92"
                },
                {
                    "start": 499,
                    "end": 501,
                    "text": "96",
                    "ref_id": "BIBREF93"
                },
                {
                    "start": 734,
                    "end": 736,
                    "text": "97",
                    "ref_id": "BIBREF94"
                },
                {
                    "start": 1276,
                    "end": 1279,
                    "text": "100",
                    "ref_id": "BIBREF97"
                }
            ],
            "ref_spans": [],
            "section": "J o u r n a l P r e -p r o o f"
        },
        {
            "text": "Moreover, activation of coagulation in healthy human subjects by the administration of recombinant factor VIIa also elicits a small but significant increase in the concentrations of IL-6 and IL-8 in plasma 101 . Thrombin too has been shown to have many non-coagulant effects, among these there is IL-6 induction in fibroblasts, epithelial cells and mononuclear cells in vitro 102 and induction of IL-8 production in endothelial cells 103 . This is evidence of a well-known cross-talking between inflammations and coagulation, and of a possible loop mechanism which could be amplified in a setting like that of COVID-19.",
            "cite_spans": [
                {
                    "start": 206,
                    "end": 209,
                    "text": "101",
                    "ref_id": "BIBREF98"
                },
                {
                    "start": 434,
                    "end": 437,
                    "text": "103",
                    "ref_id": "BIBREF100"
                }
            ],
            "ref_spans": [],
            "section": "J o u r n a l P r e -p r o o f"
        },
        {
            "text": "Targeting the endocytosis process is also possible with other drugs other than hydroxychloroquine. One known regulators of endocytosis is the AP2-associated protein kinase 1(AAK1). Using Artificial Intelligence it was possible to find a good inhibitor of AAK1 like Baricitinib, a known Janus kinase inhibitor which can reduce both viral entry and inflammation. It is a selective and powerful JAK-STAT signaling inhibitor thus being effective against the consequences of the elevated levels of cytokines, not only being able of J o u r n a l P r e -p r o o f lowering IL-6 levels 104 , but it also has the potential to inhibit clathrin-mediated endocytosis and thereby inhibit viral infection of cells. It targets members of the numb-associated kinase (NAK) family ( AAK1 and GAK), the inhibition of which has been shown to reduce viral infection in vitro 105 . It can be administered orally and has acceptable side effect profile, besides having little interaction with CYP enzymes and drug transporters 106 , since renal elimination is the principal clearance mechanism for Baricitinib 107 . It regulates innate immunity through blocking type-I IFN signal. Baricitinib downregulates CD80/CD86 expression, but not that of HLA-DR in human monocyte-derived dendritic cells in a concentration-dependent manner.",
            "cite_spans": [
                {
                    "start": 855,
                    "end": 858,
                    "text": "105",
                    "ref_id": "BIBREF102"
                },
                {
                    "start": 1004,
                    "end": 1007,
                    "text": "106",
                    "ref_id": "BIBREF103"
                }
            ],
            "ref_spans": [],
            "section": "Baricitinib"
        },
        {
            "text": "Moreover, assessment of the action of Baricitinib on plasmacytoid dendritic cells (pDC), which are the main source of type-I IFN, showed suppressed production of type-I IFN 107 . This makes Baricinitib a valid option in every phase of the viral infection, the early stages to reduce viral entry in the cells, and later stages for its anti-inflammatory properties. A Phase2/3 clinical trial is ongoing (NCT04340232) 26 .",
            "cite_spans": [
                {
                    "start": 173,
                    "end": 176,
                    "text": "107",
                    "ref_id": "BIBREF104"
                }
            ],
            "ref_spans": [],
            "section": "Baricitinib"
        },
        {
            "text": "Since high levels of IL-6 is the results or this excessive inflammatory response, one way to target IL-6 is with antibodies like Tocilizumab, another way is to counteract the response induced by IL-6. This can be done by inhibiting the JAK 1/2 pathway with drugs like Ruxolitinib. Ruxolitinib is a small drug belonging to the class of Janus kinase (JAK) inhibitors and currently clinically used in the treatment of JAK2 mutated myeloproliferative neoplasms, including myelofibrosis and polycythemia vera 108, 109 . It shows activity against the JAK2 isoform and also the JAK1 isoform, which plays a major role in the signaling pathway of inflammatory cytokines 110 . JAK3 seems to be less sensitive to ruxolitinib 111 , it also shows anti-inflammatory activity which may be beneficial in its clinical use 112 ; it is also implicated in the suppression of the harmful consequences of macrophage activation hemophagocytic lymphohistiocytosis 113 , which is an underrecognized hyperinflammatory syndrome characterized by fulminant and fatal hypercytokinemia with multi organ failure 114 . It has been proven that the expression of major inflammatory cytokines such as TNF alfa and IL-6 was highly reduced in inflammatory human macrophages exposed to ruxolitinib 112 . It has also been shown through an analysis of mRNA expression of cytokines by PCR array that the major inflammatory cytokines , IL-6 and TNF alfa, were highly reduced and down-regulated by Ruxolitinib at both protein and J o u r n a l P r e -p r o o f mRNA level 115 . Ruxolitinib has many effects on many types of cells like Natural Killers (NKs), Dendritic Cells (DCs), and T cells. NKs are usually reduced after Ruxolitinib administration, this happens after NKs maturation is impaired. Ruxolitinib profoundly impairs DCs migration; subsequently, the loss of trafficking DCs may lead to reduced activation of T cells in draining lymph nodes 116 . Also Treg cells are negatively regulated with Ruxolitinib 116 . All these results point towards a possible use of Ruxolitinib as an IL-6 inhibitor like Tocilizumab in the advanced stages of COVID-19, a trial is ongoing(NCT04334044, Phase1/2) 26 . Table 1 summarizes the main therapeutic options that have been discussed here (Table 1) .",
            "cite_spans": [
                {
                    "start": 504,
                    "end": 508,
                    "text": "108,",
                    "ref_id": "BIBREF105"
                },
                {
                    "start": 509,
                    "end": 512,
                    "text": "109",
                    "ref_id": "BIBREF106"
                },
                {
                    "start": 661,
                    "end": 664,
                    "text": "110",
                    "ref_id": "BIBREF107"
                },
                {
                    "start": 805,
                    "end": 808,
                    "text": "112",
                    "ref_id": "BIBREF109"
                },
                {
                    "start": 940,
                    "end": 943,
                    "text": "113",
                    "ref_id": "BIBREF110"
                },
                {
                    "start": 1080,
                    "end": 1083,
                    "text": "114",
                    "ref_id": "BIBREF111"
                },
                {
                    "start": 1528,
                    "end": 1531,
                    "text": "115",
                    "ref_id": "BIBREF112"
                },
                {
                    "start": 1909,
                    "end": 1912,
                    "text": "116",
                    "ref_id": "BIBREF113"
                }
            ],
            "ref_spans": [
                {
                    "start": 2162,
                    "end": 2169,
                    "text": "Table 1",
                    "ref_id": null
                },
                {
                    "start": 2240,
                    "end": 2249,
                    "text": "(Table 1)",
                    "ref_id": null
                }
            ],
            "section": "Ruxolitinib"
        },
        {
            "text": "We discussed the most valid options against COVID-19, but many new alternatives arise every day. Future possible treatments are discussed here. Inhibiting the receptor ACE2 seemed like a reasonable strategy but at the moment is controversial and has shown many possible side effects 117 . Another interestingly choice is to use a recombinant form of the ACE2 receptor to \"keep the virus busy\" and thus reduce the infected number of the cells by inhibiting the first phase, this has particularly been tested in patients with ARDS in the past 118 . Another option is targeting viral entry: cleavage and activation of SARS-CoV-1 spike protein (S) by a host cell protease is essential for viral entry, this host cell protease is called TMPRSS2. Potential in vitro proven inhibitors are camostat mesylate 119 27 , another recently discovered in vitro protease inhibitor is compound 13b, which is a modified alfa-ketoamide 121 .",
            "cite_spans": [
                {
                    "start": 283,
                    "end": 286,
                    "text": "117",
                    "ref_id": "BIBREF114"
                },
                {
                    "start": 541,
                    "end": 544,
                    "text": "118",
                    "ref_id": "BIBREF115"
                },
                {
                    "start": 640,
                    "end": 643,
                    "text": "(S)",
                    "ref_id": null
                },
                {
                    "start": 800,
                    "end": 803,
                    "text": "119",
                    "ref_id": "BIBREF116"
                },
                {
                    "start": 804,
                    "end": 806,
                    "text": "27",
                    "ref_id": "BIBREF27"
                },
                {
                    "start": 917,
                    "end": 920,
                    "text": "121",
                    "ref_id": "BIBREF118"
                }
            ],
            "ref_spans": [],
            "section": "Other possible drugs"
        },
        {
            "text": "Coagulopathy and inflammatory response are intertwined as already discussed. Both the presence of coagulation disfunction and the excessive activation of inflammatory response point towards and excessive J o u r n a l P r e -p r o o f activation of the complement system. In a murine model lacking C3 and thus unable to activate the common complement pathway, SARS-CoV-1 infection severity was reduced 122 . In a murine model of MERS-CoV infection, increased concentrations of C5a and C5b were found in the serum and in lung tissues 123 . This suggests a possible use of Eculizumab, a C5 complement inhibitor, to both prevent coagulation disorder and hyper-inflammation activation (NCT04288713) 26 .",
            "cite_spans": [
                {
                    "start": 402,
                    "end": 405,
                    "text": "122",
                    "ref_id": "BIBREF119"
                },
                {
                    "start": 533,
                    "end": 536,
                    "text": "123",
                    "ref_id": "BIBREF120"
                },
                {
                    "start": 695,
                    "end": 697,
                    "text": "26",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Other possible drugs"
        },
        {
            "text": "Targeting viral components such as the spike proteins of the virus with specific antibodies is another therapeutic option which is currently being tested 124 . Neutralizing Antibodies are active during the free circulation of the virus. Coronaviruses neutralizing antibodies usually target the spike proteins(S) on the viral surface of the virus which allow it to enter host cells. The S protein has two subunits: one that mediates cell binding, S1 consisting of 4 domains, and one that mediates cell fusion, the S2 domain. The most neutralizing antibodies are shown to target the receptor interaction site in S1 subunit [125] [126] [127] [128] [129] [130] [131] . As shown in previous studies spike proteins of SARS-CoV-2 and SARS-CoV-1 are 77.5% identical by primary amino acid sequence and structurally very similar 132, 133 , they bind the ACE2 protein 134 through the S1 subunit(S1B).",
            "cite_spans": [
                {
                    "start": 154,
                    "end": 157,
                    "text": "124",
                    "ref_id": "BIBREF121"
                },
                {
                    "start": 621,
                    "end": 626,
                    "text": "[125]",
                    "ref_id": "BIBREF122"
                },
                {
                    "start": 627,
                    "end": 632,
                    "text": "[126]",
                    "ref_id": "BIBREF123"
                },
                {
                    "start": 633,
                    "end": 638,
                    "text": "[127]",
                    "ref_id": "BIBREF124"
                },
                {
                    "start": 639,
                    "end": 644,
                    "text": "[128]",
                    "ref_id": "BIBREF125"
                },
                {
                    "start": 645,
                    "end": 650,
                    "text": "[129]",
                    "ref_id": "BIBREF126"
                },
                {
                    "start": 651,
                    "end": 656,
                    "text": "[130]",
                    "ref_id": "BIBREF127"
                },
                {
                    "start": 657,
                    "end": 662,
                    "text": "[131]",
                    "ref_id": "BIBREF128"
                },
                {
                    "start": 819,
                    "end": 823,
                    "text": "132,",
                    "ref_id": "BIBREF129"
                },
                {
                    "start": 824,
                    "end": 827,
                    "text": "133",
                    "ref_id": "BIBREF130"
                }
            ],
            "ref_spans": [],
            "section": "Other possible drugs"
        },
        {
            "text": "The latest developed antibodies showing neutralizing properties is the Human 47D11 antibody, which was shown to target the S1B receptor binding domain of SARS-CoV-1 and SARS-CoV-2. Despite its capacity to inhibit infected cells with SARS-CoV-1 and SARS-CoV-2, the binding activity did not compete with S1B to the ACE2 receptor. This seems to indicate that 47D11 neutralizes SARS-CoV-1 and SARS-CoV-2 through a yet unknown mechanism different from binding interference 124 . This study shows how, despite the high capability of the virus to mutate, targeting conserved core structure of the S1B receptor is a good strategy. This provides evidence for the design of the SARS-CoV-2 vaccine composed of viral structural proteins.",
            "cite_spans": [
                {
                    "start": 468,
                    "end": 471,
                    "text": "124",
                    "ref_id": "BIBREF121"
                }
            ],
            "ref_spans": [],
            "section": "Other possible drugs"
        },
        {
            "text": "Another possible choice is Ivermectin, which showed to inhibit viral replication of SARS-CoV-2 in vitro 135 , but in vivo studies need to evaluate its effect, clinical trials in COVID-19 are ongoing(NCT04390022, Phase 2).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Other possible drugs"
        },
        {
            "text": "The use of immunosuppressants like corticosteroids is quite controversial, for some it may be reasonable to counteract the effect of cytokine storm induced by the SARS-CoV-2. Although the recent open label study J o u r n a l P r e -p r o o f from Wu and colleagues showed a benefit for corticosteroids, for now clinical evidence does not support corticosteroid treatment for SARS-CoV-1 lung injury, as it could result in delayed viral clearence 136, 137 . Table 2 summarizes other therapeutic options that have been discussed here (Table 2 ).",
            "cite_spans": [
                {
                    "start": 446,
                    "end": 450,
                    "text": "136,",
                    "ref_id": "BIBREF133"
                },
                {
                    "start": 451,
                    "end": 454,
                    "text": "137",
                    "ref_id": "BIBREF134"
                }
            ],
            "ref_spans": [
                {
                    "start": 457,
                    "end": 464,
                    "text": "Table 2",
                    "ref_id": null
                },
                {
                    "start": 532,
                    "end": 540,
                    "text": "(Table 2",
                    "ref_id": null
                }
            ],
            "section": "Other possible drugs"
        },
        {
            "text": "In conclusions the author showed a list of possible therapies, many are being tested in clinical trials as we speak, some still need more testing. This review aimed to give an update on currently available therapies, already known drugs discussed here could have the advantage of speeding up the clinical trial process, since we already known their side effects and tolerability.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Other possible drugs"
        },
        {
            "text": "The author declares no conflict of interest.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflicts of interests:"
        },
        {
            "text": "J o u r n a l P r e -p r o o f",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflicts of interests:"
        },
        {
            "text": "Hydroxychloroquine 14, 15, 16, 18, 20, 21, 22, 25, 26 Inhibition of endosomal acidification, inhibition of glycosylation of host receptors and proteolytic processing 14 . Immunomodulatory effect 14, 18 Interaction with Spike protein Ivermectin 135, 26 Inhibition of in vitro replication NCT04390022, Phase 2 Corticosteroids 136, 137 Immunosuppression NCT04273321 Table 2 ",
            "cite_spans": [
                {
                    "start": 19,
                    "end": 22,
                    "text": "14,",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 23,
                    "end": 26,
                    "text": "15,",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 27,
                    "end": 30,
                    "text": "16,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 31,
                    "end": 34,
                    "text": "18,",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 35,
                    "end": 38,
                    "text": "20,",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 39,
                    "end": 42,
                    "text": "21,",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 43,
                    "end": 46,
                    "text": "22,",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 47,
                    "end": 50,
                    "text": "25,",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 51,
                    "end": 53,
                    "text": "26",
                    "ref_id": null
                },
                {
                    "start": 166,
                    "end": 168,
                    "text": "14",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 195,
                    "end": 198,
                    "text": "14,",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 199,
                    "end": 201,
                    "text": "18",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 244,
                    "end": 248,
                    "text": "135,",
                    "ref_id": "BIBREF132"
                },
                {
                    "start": 249,
                    "end": 251,
                    "text": "26",
                    "ref_id": null
                },
                {
                    "start": 324,
                    "end": 328,
                    "text": "136,",
                    "ref_id": "BIBREF133"
                },
                {
                    "start": 329,
                    "end": 332,
                    "text": "137",
                    "ref_id": "BIBREF134"
                }
            ],
            "ref_spans": [
                {
                    "start": 363,
                    "end": 370,
                    "text": "Table 2",
                    "ref_id": null
                }
            ],
            "section": "Mechanism of action Trial/Phase"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Coronavirus pathogenesis",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Weiss",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Leibowitz",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Adv Virus Res",
            "volume": "81",
            "issn": "",
            "pages": "85--164",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Ia",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "A"
                    ],
                    "last": "Madani",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Infect Dis",
            "volume": "91",
            "issn": "",
            "pages": "264--266",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Novel coronavirus: where we are and what we know",
            "authors": [
                {
                    "first": "Z",
                    "middle": [
                        "J"
                    ],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shan",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Structural basis of receptor recognition by SARS-CoV-2",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shang",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "She",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Bai",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Clin Transl Med",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "382",
            "issn": "",
            "pages": "1199--1207",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "The Incubation Period of Coronavirus Disease",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Lauer",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "H"
                    ],
                    "last": "Grantz",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Bi",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "From Publicly Reported Confirmed Cases: Estimation and Application",
            "authors": [],
            "year": 2020,
            "venue": "Ann Intern Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Clinical Features of 69 Cases with Coronavirus Disease",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wen",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Clin Infect Dis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "The Lancet",
            "volume": "395",
            "issn": "",
            "pages": "507--513",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Dysregulation of immune response in patients with COVID-19 in Wuhan, China",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Qin",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Clin Infect Dis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Discovering drugs to treat coronavirus disease 2019 (COVID-19)",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Drug Discov Ther",
            "volume": "14",
            "issn": "",
            "pages": "58--60",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "SARS-CoV-2 and COVID-19: What are our options?",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Magro",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Where should we focus our attention on to find new drugs and strategies? Travel Medicine and Infectious Disease",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?",
            "authors": [
                {
                    "first": "Quiros",
                    "middle": [],
                    "last": "Roldan",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Biasiotto",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Magro",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Zanella",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Pharmacological Research",
            "volume": "158",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Discov",
            "volume": "6",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gautret",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Lagier",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Parola",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Int J Antimicrob Agents",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Dai",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Tong",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Antimicrob Chemother",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "A"
                    ],
                    "last": "Devaux",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Rolain",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Colson",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Int J Antimicrob Agents",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gautret",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Lagier",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Parola",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Travel Med Infect Dis",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Zika virus cell tropism in the developing human brain and inhibition by azithromycin",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Retallack",
                    "suffix": ""
                },
                {
                    "first": "Di",
                    "middle": [],
                    "last": "Lullo",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Arias",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Proc Natl Acad Sci U S A",
            "volume": "113",
            "issn": "",
            "pages": "14408--14413",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Evaluation of Ebola Virus Inhibitors for Drug Repurposing",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "B"
                    ],
                    "last": "Madrid",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Panchal",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "K"
                    ],
                    "last": "Warren",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "ACS Infect Dis",
            "volume": "1",
            "issn": "",
            "pages": "317--326",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "B"
                    ],
                    "last": "Bacharier",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "W"
                    ],
                    "last": "Guilbert",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "T"
                    ],
                    "last": "Mauger",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "JAMA",
            "volume": "314",
            "issn": "",
            "pages": "2034--2044",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19",
            "authors": [
                {
                    "first": "Qian",
                    "middle": [],
                    "last": "Dandan",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "I"
                    ],
                    "last": "Zhiping",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Tao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "U"
                    ],
                    "last": "Shen Yinzhong",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Hongzhou",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Zhejiang Univ (Med Sci)",
            "volume": "49",
            "issn": "",
            "pages": "215--219",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Sanders",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Monogue",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "Z"
                    ],
                    "last": "Jodlowski",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Cutrell",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 1926,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "De",
                    "middle": [],
                    "last": "Clercq",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Rev Drug Discov",
            "volume": "19",
            "issn": "",
            "pages": "149--150",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Gordon",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "P"
                    ],
                    "last": "Tchesnokov",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "Y"
                    ],
                    "last": "Feng",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "P"
                    ],
                    "last": "Porter",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gotte",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Biol Chem",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "P"
                    ],
                    "last": "Sheahan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Sims",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "L"
                    ],
                    "last": "Graham",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Sci Transl Med",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Controlled Trial of Ebola Virus Disease Therapeutics",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mulangu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "E"
                    ],
                    "last": "Dodd",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "T"
                    ],
                    "last": "Davey",
                    "suffix": ""
                },
                {
                    "first": "Jr",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "N Engl J Med",
            "volume": "381",
            "issn": "",
            "pages": "2293--2303",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Brown",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Won",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "L"
                    ],
                    "last": "Graham",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Antiviral Res",
            "volume": "169",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "De Wit",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Feldmann",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Cronin",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Proc Natl Acad Sci",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Remdesivir is a direct-acting antiviral that inhibits RNAdependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Gordon",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "P"
                    ],
                    "last": "Tchesnokov",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Woolner",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Biol Chem",
            "volume": "295",
            "issn": "",
            "pages": "6785--6797",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Remdesivir in adults with severe COVID-19: a randomised, doubleblind, placebo-controlled, multicentre trial. The Lancet",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Chu",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "C"
                    ],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "F"
                    ],
                    "last": "Hung",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Thorax",
            "volume": "59",
            "issn": "",
            "pages": "252--256",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "H"
                    ],
                    "last": "De Wilde",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Jochmans",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "C"
                    ],
                    "last": "Posthuma",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Antimicrob Agents Chemother",
            "volume": "58",
            "issn": "",
            "pages": "4875--4884",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yao",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Yeung",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Infect Dis",
            "volume": "212",
            "issn": "",
            "pages": "1904--1913",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "T"
                    ],
                    "last": "Yao",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Qian",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "Y"
                    ],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "Q"
                    ],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Med Virol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "S"
                    ],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "T"
                    ],
                    "last": "Lai",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Chu",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Hong Kong Med J",
            "volume": "9",
            "issn": "",
            "pages": "399--406",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Nutho",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Mahalapbutr",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Hengphasatporn",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Biochemistry",
            "volume": "59",
            "issn": "",
            "pages": "1769--1779",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wen",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "H"
                    ],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "Y"
                    ],
                    "last": "Kao",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Infect",
            "volume": "67",
            "issn": "",
            "pages": "606--616",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Hart",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Dyall",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Postnikova",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "J Gen Virol",
            "volume": "95",
            "issn": "",
            "pages": "571--577",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "M"
                    ],
                    "last": "Arabi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alothman",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "H"
                    ],
                    "last": "Balkhy",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Trials",
            "volume": "19",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "P"
                    ],
                    "last": "Sheahan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Sims",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Leist",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat Commun",
            "volume": "11",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "K"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "Y"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "J"
                    ],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Clin Infect Dis",
            "volume": "39",
            "issn": "",
            "pages": "1071--1075",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Okabayashi",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Kariwa",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yokota",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "J Med Virol",
            "volume": "78",
            "issn": "",
            "pages": "417--424",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Mouse-passaged severe acute respiratory syndromeassociated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Nagata",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Iwata",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Hasegawa",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Am J Pathol",
            "volume": "172",
            "issn": "",
            "pages": "1625--1637",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "W"
                    ],
                    "last": "Day",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Baric",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "X"
                    ],
                    "last": "Cai",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Virology",
            "volume": "395",
            "issn": "",
            "pages": "210--222",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "The Lancet",
            "volume": "395",
            "issn": "",
            "pages": "1054--1062",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "Correlation Analysis Between Disease Severity and Inflammationrelated Parameters in Patients with",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gong",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "Q"
                    ],
                    "last": "Xia",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "J"
                    ],
                    "last": "Giamarellos-Bourboulis",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Netea",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Rovina",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Host Microbe",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Virology",
            "volume": "365",
            "issn": "",
            "pages": "324--335",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Coronavirus infections and immune responses",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Lai",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Med Virol",
            "volume": "92",
            "issn": "",
            "pages": "424--432",
            "other_ids": {}
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "Patient data, early SARS epidemic",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "Hsueh",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "J"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Hsiao",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Taiwan. Emerg Infect Dis",
            "volume": "10",
            "issn": "",
            "pages": "489--493",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation",
            "authors": [
                {
                    "first": "Rose-John S",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Clin Pharmacol Ther",
            "volume": "102",
            "issn": "",
            "pages": "591--598",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset?",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Magro",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "What is there besides Tocilizumab? SGP130Fc. Cytokine: X 2020",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "N"
                    ],
                    "last": "Lamb",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "D"
                    ],
                    "last": "Deeks",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Drugs",
            "volume": "78",
            "issn": "",
            "pages": "929--940",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Tu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Begum-Haque",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sharma",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "R"
                    ],
                    "last": "Kasper",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Neuroimmunol",
            "volume": "40",
            "issn": "",
            "pages": "58--65",
            "other_ids": {}
        },
        "BIBREF61": {
            "ref_id": "b61",
            "title": "Canakinumab for the treatment of familial Mediterranean fever",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Ozdogan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ugurlu",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Expert Rev Clin Immunol",
            "volume": "13",
            "issn": "",
            "pages": "393--404",
            "other_ids": {}
        },
        "BIBREF62": {
            "ref_id": "b62",
            "title": "Canakinumab for Atherosclerotic Disease",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Rothman",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Morton",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "C"
                    ],
                    "last": "Crossman",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Investigators M-Ih",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "N Engl J Med",
            "volume": "378",
            "issn": "",
            "pages": "197--198",
            "other_ids": {}
        },
        "BIBREF63": {
            "ref_id": "b63",
            "title": "Anakinra for the treatment of rheumatoid arthritis: a safety evaluation",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Ramirez",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Canete",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Expert Opin Drug Saf",
            "volume": "17",
            "issn": "",
            "pages": "727--732",
            "other_ids": {}
        },
        "BIBREF64": {
            "ref_id": "b64",
            "title": "Emapalumab: First Global Approval",
            "authors": [
                {
                    "first": "Al-Salama",
                    "middle": [],
                    "last": "Zt",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Drugs",
            "volume": "79",
            "issn": "",
            "pages": "99--103",
            "other_ids": {}
        },
        "BIBREF65": {
            "ref_id": "b65",
            "title": "Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Fu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "National Science Review",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF66": {
            "ref_id": "b66",
            "title": "FRI0209 MORAb-022, An Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody (MAB): Results of The First Study in Patients with Mild-To-Moderate Rheumatoid Arthritis (RA)",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Kivitz",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Hazan",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Hoffman",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "A"
                    ],
                    "last": "Wallin",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Annals of the Rheumatic Diseases",
            "volume": "75",
            "issn": "",
            "pages": "507--507",
            "other_ids": {}
        },
        "BIBREF67": {
            "ref_id": "b67",
            "title": "Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Senolt",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "8",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF68": {
            "ref_id": "b68",
            "title": "Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF69": {
            "ref_id": "b69",
            "title": "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Thromb Haemost",
            "volume": "18",
            "issn": "",
            "pages": "844--847",
            "other_ids": {}
        },
        "BIBREF70": {
            "ref_id": "b70",
            "title": "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Bai",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gong",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Thromb Haemost",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF71": {
            "ref_id": "b71",
            "title": "More than an anticoagulant: Do heparins have direct antiinflammatory effects?",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Poterucha",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Libby",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "Z"
                    ],
                    "last": "Goldhaber",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Thromb Haemost",
            "volume": "117",
            "issn": "",
            "pages": "437--444",
            "other_ids": {}
        },
        "BIBREF72": {
            "ref_id": "b72",
            "title": "The anti-inflammatory effects of heparin and related compounds",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Young",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Thromb Res",
            "volume": "122",
            "issn": "",
            "pages": "743--752",
            "other_ids": {}
        },
        "BIBREF73": {
            "ref_id": "b73",
            "title": "Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis?",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Anticancer Agents Med Chem",
            "volume": "8",
            "issn": "",
            "pages": "64--76",
            "other_ids": {}
        },
        "BIBREF74": {
            "ref_id": "b74",
            "title": "Activation of Coagulation and Fibrinolysis in Acute Respiratory Distress Syndrome: A Prospective Pilot Study",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Ozolina",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sarkele",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Sabelnikovs",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Front Med (Lausanne)",
            "volume": "3",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF75": {
            "ref_id": "b75",
            "title": "Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "J"
                    ],
                    "last": "Glas",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "F"
                    ],
                    "last": "Van Der Sluijs",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Schultz",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Hofstra",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Van Der Poll",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Levi",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Thromb Haemost",
            "volume": "11",
            "issn": "",
            "pages": "17--25",
            "other_ids": {}
        },
        "BIBREF76": {
            "ref_id": "b76",
            "title": "Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Shukla",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "G"
                    ],
                    "last": "Spear",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "J Clin Invest",
            "volume": "108",
            "issn": "",
            "pages": "503--510",
            "other_ids": {}
        },
        "BIBREF77": {
            "ref_id": "b77",
            "title": "Coronaviridae and SARS-associated coronavirus strain HSR1",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Vicenzi",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Canducci",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Pinna",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Emerg Infect Dis",
            "volume": "10",
            "issn": "",
            "pages": "413--418",
            "other_ids": {}
        },
        "BIBREF78": {
            "ref_id": "b78",
            "title": "Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Cui",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Thromb Haemost",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF79": {
            "ref_id": "b79",
            "title": "The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Malato",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Dentali",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Siragusa",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Blood Transfus",
            "volume": "13",
            "issn": "",
            "pages": "559--568",
            "other_ids": {}
        },
        "BIBREF80": {
            "ref_id": "b80",
            "title": "Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Kollias",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "G"
                    ],
                    "last": "Kyriakoulis",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Dimakakos",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Poulakou",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "S"
                    ],
                    "last": "Stergiou",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Syrigos",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Br J Haematol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF81": {
            "ref_id": "b81",
            "title": "COVID-19 Coagulopathy in Caucasian patients",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Fogarty",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Townsend",
                    "suffix": ""
                },
                {
                    "first": "Ni",
                    "middle": [],
                    "last": "Cheallaigh",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Br J Haematol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF82": {
            "ref_id": "b82",
            "title": "COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Spiezia",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Boscolo",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Poletto",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Thromb Haemost",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF83": {
            "ref_id": "b83",
            "title": "ISTH interim guidance on recognition and management of coagulopathy in COVID-19",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Thachil",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Gando",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "COVID-19 and VTE/Anticoagulation: Frequently Asked Questions",
            "volume": "18",
            "issn": "",
            "pages": "1023--1026",
            "other_ids": {}
        },
        "BIBREF84": {
            "ref_id": "b84",
            "title": "The relationship between inflammation and the coagulation system",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Choi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Schultz",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Levi",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Van Der Poll",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Swiss Med Wkly",
            "volume": "136",
            "issn": "",
            "pages": "139--144",
            "other_ids": {}
        },
        "BIBREF85": {
            "ref_id": "b85",
            "title": "Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1beta, IL-6 and IL-8",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Bester",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Matshailwe",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Pretorius",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Cytokine",
            "volume": "110",
            "issn": "",
            "pages": "237--242",
            "other_ids": {}
        },
        "BIBREF86": {
            "ref_id": "b86",
            "title": "Inflammation and atherosclerosis",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Libby",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Ridker",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Maseri",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Circulation",
            "volume": "105",
            "issn": "",
            "pages": "1135--1143",
            "other_ids": {}
        },
        "BIBREF87": {
            "ref_id": "b87",
            "title": "Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "E"
                    ],
                    "last": "Van Aken",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "H"
                    ],
                    "last": "Reitsma",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "R"
                    ],
                    "last": "Rosendaal",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Br J Haematol",
            "volume": "116",
            "issn": "",
            "pages": "173--177",
            "other_ids": {}
        },
        "BIBREF88": {
            "ref_id": "b88",
            "title": "Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "H"
                    ],
                    "last": "Reitsma",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "R"
                    ],
                    "last": "Rosendaal",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Thromb Haemost",
            "volume": "2",
            "issn": "",
            "pages": "619--622",
            "other_ids": {}
        },
        "BIBREF89": {
            "ref_id": "b89",
            "title": "The proinflammatory cytokine response to coagulation and endotoxin in whole blood",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Johnson",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Aarden",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Choi",
                    "suffix": ""
                },
                {
                    "first": "De",
                    "middle": [],
                    "last": "Groot",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Creasey",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Blood",
            "volume": "87",
            "issn": "",
            "pages": "5051--5060",
            "other_ids": {}
        },
        "BIBREF90": {
            "ref_id": "b90",
            "title": "Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wichmann",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Sperhake",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Lutgehetmann",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Ann Intern Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF91": {
            "ref_id": "b91",
            "title": "Inflammation, sepsis, and coagulation",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "T"
                    ],
                    "last": "Esmon",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Fukudome",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Mather",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Haematologica",
            "volume": "84",
            "issn": "",
            "pages": "254--259",
            "other_ids": {}
        },
        "BIBREF92": {
            "ref_id": "b92",
            "title": "Two-way interactions between inflammation and coagulation",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Levi",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Van Der Poll",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Trends Cardiovasc Med",
            "volume": "15",
            "issn": "",
            "pages": "254--259",
            "other_ids": {}
        },
        "BIBREF93": {
            "ref_id": "b93",
            "title": "Inflammation and coagulation",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Levi",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Van Der Poll",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Crit Care Med",
            "volume": "38",
            "issn": "",
            "pages": "26--34",
            "other_ids": {}
        },
        "BIBREF94": {
            "ref_id": "b94",
            "title": "Interleukin 6 and haemostasis",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Kerr",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Stirling",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "A"
                    ],
                    "last": "Ludlam",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Br J Haematol",
            "volume": "115",
            "issn": "",
            "pages": "3--12",
            "other_ids": {}
        },
        "BIBREF95": {
            "ref_id": "b95",
            "title": "Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "Y"
                    ],
                    "last": "Senchenkova",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Komoto",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Russell",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Am J Pathol",
            "volume": "183",
            "issn": "",
            "pages": "173--181",
            "other_ids": {}
        },
        "BIBREF96": {
            "ref_id": "b96",
            "title": "Effects of IL-1beta, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Bester",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Pretorius",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Sci Rep",
            "volume": "6",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF97": {
            "ref_id": "b97",
            "title": "Platelet activation induced by human antibodies to interleukin-8",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Regnault",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "De Maistre",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Carteaux",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Blood",
            "volume": "101",
            "issn": "",
            "pages": "1419--1421",
            "other_ids": {}
        },
        "BIBREF98": {
            "ref_id": "b98",
            "title": "Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "De Jonge",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "W"
                    ],
                    "last": "Friederich",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "P"
                    ],
                    "last": "Vlasuk",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Clin Diagn Lab Immunol",
            "volume": "10",
            "issn": "",
            "pages": "495--497",
            "other_ids": {}
        },
        "BIBREF99": {
            "ref_id": "b99",
            "title": "Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Johnson",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Choi",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Degroot",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Samuels",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Creasey",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Aarden",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "J Immunol",
            "volume": "160",
            "issn": "",
            "pages": "5130--5135",
            "other_ids": {}
        },
        "BIBREF100": {
            "ref_id": "b100",
            "title": "Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Kahn",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Nakanishi-Matsui",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Shapiro",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Ishihara",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Coughlin",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "J Clin Invest",
            "volume": "103",
            "issn": "",
            "pages": "879--887",
            "other_ids": {}
        },
        "BIBREF101": {
            "ref_id": "b101",
            "title": "Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Choi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Cooper",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Staser",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Leukemia",
            "volume": "32",
            "issn": "",
            "pages": "2483--2494",
            "other_ids": {}
        },
        "BIBREF102": {
            "ref_id": "b102",
            "title": "Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Bekerman",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Neveu",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Shulla",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "J Clin Invest",
            "volume": "127",
            "issn": "",
            "pages": "1338--1352",
            "other_ids": {}
        },
        "BIBREF103": {
            "ref_id": "b103",
            "title": "COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Stebbing",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Phelan",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Griffin",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF104": {
            "ref_id": "b104",
            "title": "Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Kubo",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Nakayamada",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Tanaka",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Expert Review of Clinical Immunology",
            "volume": "15",
            "issn": "",
            "pages": "693--700",
            "other_ids": {}
        },
        "BIBREF105": {
            "ref_id": "b105",
            "title": "Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Verstovsek",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Kantarjian",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Mesa",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "N Engl J Med",
            "volume": "363",
            "issn": "",
            "pages": "1117--1127",
            "other_ids": {}
        },
        "BIBREF106": {
            "ref_id": "b106",
            "title": "Emerging treatments for classical myeloproliferative neoplasms",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Vannucchi",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "N"
                    ],
                    "last": "Harrison",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Blood",
            "volume": "129",
            "issn": "",
            "pages": "693--703",
            "other_ids": {}
        },
        "BIBREF107": {
            "ref_id": "b107",
            "title": "Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Mesa",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "IDrugs",
            "volume": "13",
            "issn": "",
            "pages": "394--403",
            "other_ids": {}
        },
        "BIBREF108": {
            "ref_id": "b108",
            "title": "Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Quintas-Cardama",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Vaddi",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Blood",
            "volume": "115",
            "issn": "",
            "pages": "3109--3117",
            "other_ids": {}
        },
        "BIBREF109": {
            "ref_id": "b109",
            "title": "The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Bjorn",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "C"
                    ],
                    "last": "Hasselbalch",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Clin Case Rep",
            "volume": "3",
            "issn": "",
            "pages": "499--503",
            "other_ids": {}
        },
        "BIBREF110": {
            "ref_id": "b110",
            "title": "Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Maschalidi",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "E"
                    ],
                    "last": "Sepulveda",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Garrigue",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Fischer",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "De Saint Basile",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Blood",
            "volume": "128",
            "issn": "",
            "pages": "60--71",
            "other_ids": {}
        },
        "BIBREF111": {
            "ref_id": "b111",
            "title": "COVID-19: consider cytokine storm syndromes and immunosuppression",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Mehta",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "F"
                    ],
                    "last": "Mcauley",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Brown",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Sanchez",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Tattersall",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Manson",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "The Lancet",
            "volume": "395",
            "issn": "",
            "pages": "1033--1034",
            "other_ids": {}
        },
        "BIBREF112": {
            "ref_id": "b112",
            "title": "Repression of interferon betaregulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Febvre-James",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Lecureur",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Augagneur",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mayati",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Fardel",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Int Immunopharmacol",
            "volume": "54",
            "issn": "",
            "pages": "354--365",
            "other_ids": {}
        },
        "BIBREF113": {
            "ref_id": "b113",
            "title": "Mechanisms Underlying the Antiinflammatory and Immunosuppressive Activity of Ruxolitinib",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Elli",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Barat\u00e8",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Mendicino",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Palandri",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Palumbo",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Front Oncol",
            "volume": "9",
            "issn": "",
            "pages": "1186--1186",
            "other_ids": {}
        },
        "BIBREF114": {
            "ref_id": "b114",
            "title": "Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "P"
                    ],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Penn-Nicholson",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "W"
                    ],
                    "last": "Cho",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Virology",
            "volume": "350",
            "issn": "",
            "pages": "15--25",
            "other_ids": {}
        },
        "BIBREF115": {
            "ref_id": "b115",
            "title": "A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Khan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Benthin",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Zeno",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Crit Care",
            "volume": "21",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF116": {
            "ref_id": "b116",
            "title": "Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kawase",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Shirato",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Van Der Hoek",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Taguchi",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Matsuyama",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Virol",
            "volume": "86",
            "issn": "",
            "pages": "6537--6545",
            "other_ids": {}
        },
        "BIBREF117": {
            "ref_id": "b117",
            "title": "Protease inhibitors targeting coronavirus and filovirus entry",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Vedantham",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Antiviral Res",
            "volume": "116",
            "issn": "",
            "pages": "76--84",
            "other_ids": {}
        },
        "BIBREF118": {
            "ref_id": "b118",
            "title": "Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors",
            "authors": [
                {
                    "first": "Linlin",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "L"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Xinyuanyuan",
                    "middle": [],
                    "last": "Sun1",
                    "suffix": ""
                },
                {
                    "first": "Ute",
                    "middle": [],
                    "last": "Curth",
                    "suffix": ""
                },
                {
                    "first": "Christian",
                    "middle": [],
                    "last": "Drosten",
                    "suffix": ""
                },
                {
                    "first": "Lucie",
                    "middle": [],
                    "last": "Sauerhering",
                    "suffix": ""
                },
                {
                    "first": "Stephan",
                    "middle": [],
                    "last": "Becker",
                    "suffix": ""
                },
                {
                    "first": "Katharina",
                    "middle": [],
                    "last": "Rox",
                    "suffix": ""
                },
                {
                    "first": "Rolf",
                    "middle": [],
                    "last": "Hilgenfeld",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Science",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF119": {
            "ref_id": "b119",
            "title": "Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "E"
                    ],
                    "last": "Gralinski",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "P"
                    ],
                    "last": "Sheahan",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "E"
                    ],
                    "last": "Morrison",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "mBio",
            "volume": "9",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF120": {
            "ref_id": "b120",
            "title": "Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Emerg Microbes Infect",
            "volume": "7",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF121": {
            "ref_id": "b121",
            "title": "A human monoclonal antibody blocking SARS-CoV-2 infection",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Drabek",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF122": {
            "ref_id": "b122",
            "title": "Structural basis for the divergence of substrate specificity and biological function within HAD phosphatases in lipopolysaccharide and sialic acid biosynthesis",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "D"
                    ],
                    "last": "Daughtry",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Malashkevich",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Biochemistry",
            "volume": "52",
            "issn": "",
            "pages": "5372--5386",
            "other_ids": {}
        },
        "BIBREF123": {
            "ref_id": "b123",
            "title": "Structural Basis for the Regulation of the MmpL Transporters of Mycobacterium tuberculosis",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Delmar",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "H"
                    ],
                    "last": "Chou",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "C"
                    ],
                    "last": "Wright",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "J Biol Chem",
            "volume": "290",
            "issn": "",
            "pages": "28559--28574",
            "other_ids": {}
        },
        "BIBREF124": {
            "ref_id": "b124",
            "title": "Structural basis for outer membrane lipopolysaccharide insertion",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Gu",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Nature",
            "volume": "511",
            "issn": "",
            "pages": "52--56",
            "other_ids": {}
        },
        "BIBREF125": {
            "ref_id": "b125",
            "title": "Structural basis for the interaction of lipopolysaccharide with outer membrane protein H (OprH) from Pseudomonas aeruginosa",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "C"
                    ],
                    "last": "Edrington",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Kintz",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Goldberg",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "K"
                    ],
                    "last": "Tamm",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Biol Chem",
            "volume": "286",
            "issn": "",
            "pages": "39211--39223",
            "other_ids": {}
        },
        "BIBREF126": {
            "ref_id": "b126",
            "title": "Structural basis for activation of an integral membrane protease by lipopolysaccharide",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Eren",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Van Den Berg",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Biol Chem",
            "volume": "287",
            "issn": "",
            "pages": "23971--23976",
            "other_ids": {}
        },
        "BIBREF127": {
            "ref_id": "b127",
            "title": "Structural basis for full-spectrum inhibition of translational functions on a tRNA synthetase",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Fang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Jeong",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Nat Commun",
            "volume": "6",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF128": {
            "ref_id": "b128",
            "title": "Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Widjaja",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Van Haperen",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Emerg Microbes Infect",
            "volume": "8",
            "issn": "",
            "pages": "516--530",
            "other_ids": {}
        },
        "BIBREF129": {
            "ref_id": "b129",
            "title": "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wrapp",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "S"
                    ],
                    "last": "Corbett",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Science",
            "volume": "367",
            "issn": "",
            "pages": "1260--1263",
            "other_ids": {}
        },
        "BIBREF130": {
            "ref_id": "b130",
            "title": "Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Walls",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "J"
                    ],
                    "last": "Park",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Tortorici",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wall",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "T"
                    ],
                    "last": "Mcguire",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Veesler",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF131": {
            "ref_id": "b131",
            "title": "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Moore",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Vasilieva",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Nature",
            "volume": "426",
            "issn": "",
            "pages": "450--454",
            "other_ids": {}
        },
        "BIBREF132": {
            "ref_id": "b132",
            "title": "The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Caly",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Druce",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Catton",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Jans",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "M"
                    ],
                    "last": "Wagstaff",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Antiviral Res",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF133": {
            "ref_id": "b133",
            "title": "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Russell",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "E"
                    ],
                    "last": "Millar",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "K"
                    ],
                    "last": "Baillie",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "473--475",
            "other_ids": {}
        },
        "BIBREF134": {
            "ref_id": "b134",
            "title": "Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "JAMA Intern Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": ". Coronaviruses are equipped with exonuclease proofreading enzyme, that makes nucleotide analogues generally a poor therapeutic choice, surprisingly Remdesivir was effective against SARS-CoV-1 and MERS-CoV 29 . Tissue culture studies have shown that Remdesivir is also active against a wide number of highly different coronaviruses including human CoVs, showing a broad-sprectrum anti-CoV activity 31 . Mouse models of SARS-CoV-1 pathogenesis show that early therapy and administration of Remdesivir significantly reduced the presence of the virus in the lungs. Treated animals showed improved clinical signs of disease compared to untreated control animals 29 . Therapeutic and prophylactic use of Remdesivir has recently been tested in nonhuman primate model of MERS-CoV infection. Administration of the drug 24 hours prior to inoculation prevented the virus from inducing clinical disease and prevented replication in respiratory tissue, thus preventing lung lesions to form. Therapeutic usage of Remdesivir (12 hours after inoculation) showed similar results 32 . SARS-CoV-2 RdRp is composed of the nonstructural proteins nsp8 and nsp12. Enzyme kinetics recently showed that this RdRp efficiently incorporates the active triphosphate form of Remdesivir into RNA 33 . Since human safety data are showing promising results 30 , human clinical trials are ongoing. Remdesivir is usually well tolerated, uncommon adverse effects are elevated transaminases and kidney injury; no significant interactions occur with CYP enzymes 24 . Intravenous infusion phase 1 clinical trials are showing good safety and pharmacokinetics properties 24 . The National Institute of Health is sponsoring a randomized double-blind clinical trial comparing Remdesivir with standard of care (NCT04280705, Phase 3) 26 . Hospitalized patients with advanced COVID-19 and lung involvement who received Remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from this randomized, controlled trial involving 1063 patients. Results are quite controversial between different studies. An example of that is another trial (NCT04257656, Phase 3) of 237 patients, that showed no statistical significant benefits with Remdesivir 34 .",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": ". Adverse effects of Lopinavir/ritonavir include gastrointestinal distress such as nausea and diarrhea, and hepatotoxicity 24 . Major drug-drug interactions occur with CYP3A4, CYP2D6, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and P-glicoprotein 24 . Cao and colleagues reported the results of an open-label randomized clinical trial (ChiCTR2000029308) comparing the efficacy of lopinavir/ritonavir versus standard care in 199 patients with COVID-19. Time to clinical improvement was similar in both groups, no significant differences in viral clearance and in mortality rates were observed 41 .",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Tocilizumab a reasonable choice? Fighting the cytokine storm. SARS-CoV-1, MERS-CoV and SARS-CoV-2 show a relatively higher mortality rates then other coronaviruses and are associated with a cytokine storm, this might suggest that inflammatory responses might play a role in the pathogenesis. If that is the case, targeting the coronavirus alone with antiviral therapy might not be enough to reverse highly pathogenic infections. These observations led to explore the usage of therapies that included type I and II interferons. Interferon beta displayed the best efficacy in reducing MERS-CoV replication in tissue culture 42, 43 . A randomized control trial is ongoing in South Arabia (MIRACLE Trial) to determine whether the combination of Lopinavir/Ritonavir and Interferon beta could improve clinical outcomes in MERS-CoV infections 44 . In a humanized transgenic mouse MERS-CoV infection model, remdesivir showed more activity and efficacy in prophylactic and therapeutic use then the combination of Lopinavir/Ritonavir and Interferon beta 45 . Triple combination of interferon beta-1b, lopinavir/ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 is being tested in an open-label, randomized, phase 2 trial (NCT04276688). Early triple antiviral therapy was safe and superior to lopinavir/ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay 46 .",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": ". Since high levels of IL-6 are associated with SARS-CoV-1 and SARS-CoV-2 infections as shown above and since high serum levels of IL-6 have been associated with lung lesions in SARS-CoV-2 patients in the acute and later stages 47, 51-54, 57 , a valid option could be targeting the expression of IL-6 with Tocilizumab a monoclonal antibody against IL-6 Receptor: this option is currently being tested in some patients in Italy with extreme lung injuries (NCT04317092) 26 . This option should be approached only when there are radiological and clinical signs of progression of the lung lesions. Common side effects of Tocilizumab include increase in upper respiratory tract infections, headache, hypertension, hepatotoxicity, infusion related reactions.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Th) 1 cells and generate Granulocyte-macrophage colony-stimulating factor (GM-CSF). The cytokines environment induces inflammatory CD14 + CD16 + monocytes with high expression of IL-6 and accelerate the inflammation67 . Since IL-6 is not the only responsible of the inflammation, targeting GM-CSF is another possible therapy which has led to the developing and use of anti-GM-CSF antibodies like Gimsilumab.Gimsilumab (MORAb-022) is an investigational, fully human IgG1 monoclonal antibody being evaluated for its potential in the treatment of multiple inflammatory diseases and cancer. It targets granulocyte-disorder: is heparin the answer?Is the hyper-inflammatory state the only cause of acute lung injuries? Some studies are starting to show the presence of an associated coagulopathy and, in some cases, antiphospholipid antibodies in patients with COVID-19 who showed multiple infarcts. These patients had evidence of ischemia in the lower limbs, in the hands and bilateral cerebral infarcts in multiple vascular territories70 . These results show a systemic coagulation disorder, but it is possible that the coagulopathy starts in the lungs, and only after it spreads into the other organs. This might suggest that death occurs not only because of the inflammatory response but also because of the local coagulation disorder. Coagulopathy in SARS-CoV-2 infection has been shown to be associated with high mortality, with elevated D-dimer levels and elevated fibrinogen degradation products (FDP) being particularly important markers for the coagulopathy. A comparative analysis between survivors and non-survivors pneumonia patients revealed significantly higher D-dimers, FDP levels, longer",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": ". Many mechanisms might contribute to increased VTE risks in COVID-19 patients including: endothelial damage, microvascular thrombosis and occlusion, or even autoimmune mechanism 70 . Interestingly, in a recent study of 83 patients, despite the evidence of a progressive COVID-19 coagulopathy over time in some patients, none of those maintained on prophylactic Low-molecular-weight heparin (LMWH) developed systemic DIC. The authors propose also the existence of a pulmonary specific vasculopathy and notice how the ACE2 receptor utilized by SARS-CoV-2 is expressed on both type II pneumocytes and vascular endothelial cells within the lungs, suggesting a possible direct infection and/or damage of those cells by SARS-CoV-2 83 . Moreover, the cytokine storm associated with COVID-19 could very well be responsible for the thrombin generation and fibrin deposition within the lungs. Interestingly, a recent study showed markedly hypercoagulable thromboelastometry profiles in COVID-19 patients, thus showing how patients with acute respiratory failure may present a severe J o u r n a l P r e -p r o o f hypercoagulability rather than a consumptive coagulopathy 84 . Recent statements by the International Society on Thrombosis and Haemostasis (ISTH) and the American Society of Hematology suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis or full therapeutic-intensity anticoagulation 85, 86 . A Randomized, Open-label Phase 3 Clinical Trial is ongoing to study prevention of COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low-and High-dose Anticoagulation with Enoxaparin (NCT04345848) 26 .",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "summarizes other possible therapeutic compounds in SARS-CoV-2 infection J o u r n a l P r e -p r o o f",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "and K11777 120 , a clinical trial is ongoing for camostat mesylate in COVID-19 patients (NCT04321096 Phase1/2) 26 . Targeting the RNA-dependent RNA polymerase (RDRp) can be done with Favipiravir a drug belonging to the same class as Remdesivir 12 , a clinical trial is ongoing to study Favipiravir against standard of care (NCT04358549, Phase 2) 26 . Targeting the Main protease proteins is what Lopinavir/Ritonavir does",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": ". Iron homeostasis alteration14 .Table 1summarizes main drugs against SARS-CoV-2 and clinical trialsJ o u r n a l P r e -p r o o f",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}